What is Oruka Therapeutics, Inc.'s exchange offer (note 12)?

Oruka Therapeutics, Inc. (ORKA) reported exchange offer (note 12) of $52.83M in Q4 2024.

What does exchange offer (note 12) mean?

Represents the aggregate value of securities exchanged or converted as part of a formal exchange offer or capital restructuring. This metric tracks the movement between different classes of equity or debt-to-equity conversions. It helps investors assess changes in the company's equity base and potential dilution effects.

Oruka Therapeutics, Inc. ORKA Exchange Offer (Note 12)

Exchange Offer (Note 12) at other companies

Oruka Therapeutics, Inc.ORKA

$52.83M—

MacerichMAC

$5.23M+4,335%

ServiceTitan, Inc.TTAN

$348.97K—

KEE

Keel Infrastructure Corp. Common StockKEEL

$50M—

UDRUDR

$3.35M+50.9%

AESAES

$0—

Other financials

Income statement

See full

Revenue-—

Operating income-$36.4M-45.2%

Net income-$31.8M-51.5%

EPS (diluted)-$0.46+93.4%

Balance sheet

See full

Cash & equivalents$49.5M-40.7%

Total debt$1.8M+90.8%

Total equity$486.7M+33.4%

Total assets$504.5M+33.8%

Cash flow

See full

Operating cash flow-$23.6M-13.0%

CapEx$73.0K+462%

Free cash flow-$23.7M-13.3%

Valuation

See full

Market cap$4.36B+533%

Enterprise value$4.32B+690%

Returns & leverage

See full

Return on equity-27.3%-11.1pp

Debt / equity0×0.0×

Current ratio23.8×-6.3×

Where this comes from

Reported directly by Oruka Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ConversionOfStockAmountConverted1.

The official record: Oruka Therapeutics, Inc.’s 10-K, filed March 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Oruka Therapeutics, Inc.'s exchange offer (note 12).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Oruka Therapeutics, Inc.'s exchange offer (note 12)?: Oruka Therapeutics, Inc. (ORKA) reported exchange offer (note 12) of $52.83M in Q4 2024.
What does exchange offer (note 12) mean?: Represents the aggregate value of securities exchanged or converted as part of a formal exchange offer or capital restructuring. This metric tracks the movement between different classes of equity or debt-to-equity conversions. It helps investors assess changes in the company's equity base and potential dilution effects.